Zevra Therapeutics, Inc. (ZVRA) Aandelenanalyse

Bedrijfsoverzicht

Zevra Therapeutics, Inc. is a commercial-stage biotechnology enterprise dedicated to addressing unmet medical needs for the treatment of rare diseases within the United States market. The company operates specifically within the Healthcare sector and the Biotechnology industry, utilizing its proprietary Ligand Activated Technology platform to develop its product candidates, with KP1077 currently serving as its lead asset. As of the latest reporting period, the entity maintains a market capitalization of $556.00M, generates annual revenue of $106.47M, and employs a workforce of 61 individuals. These financial figures indicate that Zevra holds a significant market capitalization relative to its current revenue stream, suggesting a valuation that places a high premium on future product potential rather than immediate cash flow generation. The disparity between the $556.00M market cap and the $106.47M revenue highlights the market's expectation of substantial future growth derived from its rare disease portfolio and the commercialization of its lead product candidate.

Financiële gezondheid

The company reported a total revenue of $106.47M over the trailing twelve months, accompanied by a net income of $77.58M and an EBITDA of $-179,000. The substantial gap between the reported net income and the negative EBITDA reveals a specific cost structure where non-operating income or significant gains, likely from equity investments or other comprehensive income, are inflating the net profit figure while core operational expenses, when adjusted for interest and taxes, still result in a negative EBITDA. Free cash flow for the period stood at $-1,955,250, which indicates that the company is currently burning cash to fund its research and development activities, limiting immediate financial flexibility for external acquisitions or share buybacks. Despite the negative operational cash flow, the company holds a robust cash balance of $191.01M, which provides a substantial buffer against its total debt of $63.21M. The balance sheet can be characterized as moderately leveraged given a debt-to-equity ratio of 40.87, though the high liquidity position mitigates immediate solvency risks. Liquidity is further underscored by a current ratio of 5.68, which signifies an exceptionally strong ability to cover short-term liabilities with short-term assets. Return on Equity is reported at an impressive 85.7%, while Return on Assets is -1.1%, a divergence that suggests the company is utilizing shareholder equity highly efficiently in terms of profit generation but is not yet generating sufficient operating profits relative to its total asset base to offset interest and other costs effectively.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is 7.01, while the forward P/E is projected to be 6.23. The difference between these two metrics implies that the market expects earnings growth that would allow the stock to trade at a lower multiple in the future, although the current high valuation suggests confidence in rapid future expansion. The price-to-book ratio stands at 3.48, indicating that the market values the company at a significant premium of more than three times its net asset value, reflecting the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 5.22 and an EV/EBITDA of -2392.14, which suggests that traditional earnings-based multiples are less relevant due to the negative EBITDA, forcing reliance on revenue multiples to gauge value. Regarding trading range, the stock has a 52-week high of $13.16 and a 52-week low of $6.77, placing the current share price in a volatile zone that requires careful monitoring of technical support levels. The beta value is 0.89, meaning the stock is slightly less volatile than the broader market, exhibiting price movements that are marginally dampened relative to overall market fluctuations.

Growth & Income

Revenue growth year-over-year is reported at 183.4%, while earnings growth is listed as N/A due to the lack of prior year comparative data in the provided metrics. The absence of historical earnings growth data prevents a direct comparison of earnings velocity against revenue, but the massive revenue expansion suggests rapid commercialization success or significant market capture in its rare disease indications. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders. Instead, the company reinvests all available earnings and cash reserves directly back into the business to fund clinical trials and platform development. This growth-oriented capital allocation strategy is typical for early-to-mid-stage biotechnology firms that prioritize product development over income generation for investors.